Angina Pectoris News and Research

RSS

Lowering homocysteine with B-vitamins does not reduce cardiovascular risk

Secondary prevention with homocysteine-lowering B-vitamins does not reduce risk of death or major cardiovascular events, according to the WENBIT study.

3 Sep 2007

Long term follow up of additional Swedish registry data does not indicate an increased

Four years of follow up including additional patients in the Swedish Coronary angiography and angioplasty registry (SCAAR) does no longer indicate any increased mortality in patients treated with drug eluting stents compared to patients treated with bare metal stents.

2 Sep 2007

Actavis receives FDA OK for generic Inderal capsules

Actavis Group has announced that it has received approval from the U.S. Food & Drug Administration to market Propranolol Hydrochloride extended-release capsules. Distribution of the product will commence immediately.

13 Aug 2007

Caraco Pharmaceutical Labs announces FDA approval to market generic Tenormin

Caraco Pharmaceutical Laboratories has announced that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Atenolol Tablets USP (atenolol).

12 Jul 2007

Trial of percutaneous coronary intervention added to optimal medical therapy in patients with stable coronary heart disease

Percutaneous coronary interventions (PCI) involve opening partially blocked arteries to improve blood flow to the heart. These procedures are performed more than 1 million times a year.

3 Apr 2007

Ranbaxy granted approval to manufacture Atenolol

Ranbaxy Laboratories has announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Atenolol Tablets USP, 25 mg, 50 mg, and 100 mg.

2 Jan 2007

One of the largest Japanese cardiovascular trials confirms angiotensin receptor blockade protects people who have a wide range of cardiovascular diseases

The first controlled large-scale intervention trial of angiotensin receptor blockade in Japanese patients has confirmed that the cardiovascular protective effects of the drug valsartan is greater than to those seen with other therapies giving the same level of blood pressure control.

5 Sep 2006

Coronary stents that release the drugs sirolimus or paclitaxel produce similar results

Use of coronary stents that release the drugs sirolimus or paclitaxel produced similar results in patients with new coronary artery lesions, according to a study in JAMA: The Journal of the American Medical Association.

24 Feb 2006

Coffee may impair peak heart function

In healthy volunteers, the equivalent of two cups of coffee reduced the body's ability to boost blood flow to the heart muscle in response to exercise, and the effect was stronger when the participants were in a chamber simulating high altitude, according to a new study in the Jan. 17, 2006, issue of the Journal of the American College of Cardiology.

16 Jan 2006

Clarithromycin reduces recurrent cardiovascular events in patients without periodontitis

Periodontitis, an infection of the gingiva and tooth-supporting tissues, may influence the effectiveness of antibiotics used for the prevention of recurrent cardiovascular events.

5 Jan 2006

Innovative new treatment for moderate to severe heart failure

Cardiologists at Beth Israel Medical Center are currently enrolling patients in an investigational study that is looking at the safety and efficacy of an innovative new treatment for moderate to severe heart failure, in which a unique pacemaker-like device helps strengthen the heart's pumping power

26 Sep 2005

Viagra fights heart and lung diseases

German researchers have reported on the impact of Viagra on pulmonary hypertension at the Frontiers of Vascular Medicine Conference at Monash University this week.

30 Aug 2005

Vascular disease most common cause of male erectile dysfunction

A preeminent cardiologist reports, for the first time in a large prospective study, that certain of his patients with erectile dysfunction (ED) and heart problems can now safely use erection drugs that help up to 80% of men restore function and quality of life.

21 Jun 2005

Gene therapy shows effect in heart patients

The first double-blind, placebo-controlled randomized trial of VEGF gene injections into the heart muscle of patients with coronary artery disease with the intention of spurring growth of new blood vessels showed significant effects on heart wall motion, although blood flow was not significantly better in treated patients, according to a new study in the April 5, 2005, issue of the Journal of the American College of Cardiology.

5 Apr 2005

Calcium channel blocker reduces adverse cardiovascular events

The calcium channel blocker amlodipine decreases the risk of cardiovascular events (such as heart attack or heart-disease related deaths) in patients with coronary artery disease and normal blood pressure, as does the ACE inhibitor enalapril, but to a lesser extent, according to a study in the November 10 issue of JAMA.

10 Nov 2004

Angina drug nifedipine safe for long-term use

Calcium antagonists such as nifedipine are used to relieve the symptoms of angina, but there have been doubts about their long-term safety. However, ACTION--A Coronary disease Trial Investigating Outcome with Nifedipine GITS--provides new information on the drug's long-term use. GITS (gastrointestinal therapeutic system) modifies the release of the drug to provide stable long-term concentrations of nifedipine in blood.

30 Aug 2004

The proper use of drugs to treat heart disease reduces the need for hospital interventions

Regular attacks of chest pain induced by exercise (angina pectoris) is a common condition caused by blockages of the blood vessels that supply the heart (coronary heart disease).

29 Aug 2004

About one in 35 adult Americans is at high risk of coronary heart disease

About one in 35 adult Americans is at high risk of coronary heart disease, meaning they have a greater than 20 percent chance of developing heart disease within 10 years, and about one in six has a 10-year risk that is greater than 10 percent, according to a new study in the May 19, 2004 issue of the Journal of the American College of Cardiology.

19 May 2004